Advertisement

Molecular Medicine

, Volume 17, Issue 11–12, pp 1383–1396 | Cite as

Selective IgA Deficiency in Autoimmune Diseases

  • Ning Wang
  • Nan Shen
  • Timothy J. Vyse
  • Vidya Anand
  • Iva Gunnarson
  • Gunnar Sturfelt
  • Solbritt Rantapää-Dahlqvist
  • Kerstin Elvin
  • Lennart Truedsson
  • Bengt A. Andersson
  • Charlotte Dahle
  • Eva Örtqvist
  • Peter K. Gregersen
  • Timothy W. Behrens
  • Lennart Hammarström
Open Access
Invited Review Article

Abstract

Selective immunoglobulin A deficiency (IgAD) is the most common primary immunodeficiency in Caucasians. It has previously been suggested to be associated with a variety of concomitant autoimmune diseases. In this review, we present data on the prevalence of IgAD in patients with Graves disease (GD), systemic lupus erythematosus (SLE), type 1 diabetes (T1D), celiac disease (CD), myasthenia gravis (MG) and rheumatoid arthritis (RA) on the basis of both our own recent large-scale screening results and literature data. Genetic factors are important for the development of both IgAD and various autoimmune disorders, including GD, SLE, T1D, CD, MG and RA, and a strong association with the major histocompatibility complex (MHC) region has been reported. In addition, non-MHC genes, such as interferon-induced helicase 1 (IFIH1) and c-type lectin domain family 16, member A (CLEC16A), are also associated with the development of IgAD and some of the above diseases. This indicates a possible common genetic background. In this review, we present suggestive evidence for a shared genetic predisposition between these disorders.

Introduction

Selective immunoglobulin A deficiency (IgAD) is the most common primary immunodeficiency with a frequency of 1 in 600 in Caucasians (1). The prevalence in various ethnic groups ranges from 1:155 in Spain (2) to 1:18,550 in Japan (3) (for additional data, see refs. 4 and 5). The current definition, established by the Pan-American Group for Immunodeficiency and the European Society for Immunodeficiencies, defines the disorder as serum IgA levels <0.07 g/L with normal IgM and IgG levels in individuals ≥4 years of age (6).

Most individuals with IgAD are clinically asymptomatic, but the defect may be associated with recurrent respiratory and gastrointestinal tract infections/disorders, autoimmunity and allergies. Patients with IgAD are usually more prone to infections when concomitant IgG subclass deficiency is present (7).

IgAD is strongly associated with the major histocompatibility complex (MHC) region, in particular with the human leukocyte antigen (HLA)-B8, DR3, DQ2 (8.1) haplotype (8,9), and up to 45% of IgAD patients have at least one copy of this haplotype compared to 16% in the general population (10). Homozygosity for the ancestral 8.1 haplotype increases the risk of development of the disease even further (10). Other haplotypes, including HLA-DR7, DQ2 and DR1, DQ5 are also associated with IgAD (11). In contrast, the DR15, DQ6 haplotype has been shown to confer an almost complete protection against the disorder (12, 13, 14). Polymorphisms in the non-MHC genes interferoninduced helicase 1 (IFIH1) and c-type lectin domain family 16, member A (CLEC16A) genes have also been shown to be associated with IgAD in a recent genome-wide association study (GWAS) (13).

Interestingly, the ancestral 8.1 haplotype is also reported to be associated with Graves disease (GD), systemic lupus erythematosus (SLE), type 1 diabetes (T1D) and celiac disease (CD) (15,16). In addition, telomeric portions of this haplotype have also been shown to contain a risk factor for myasthenia gravis (MG) (17) and rheumatoid arthritis (RA) (18). Moreover, there are several non-MHC genes in common that have also been shown to be associated with these autoimmune disorders. It is therefore possible that IgAD and selected autoimmune disorders share some of the predisposing genes, thus explaining the increased prevalence of IgAD in certain patient groups.

IgAD and Graves Disease

GD is one of the most prevalent autoimmune thyroid disorders (19). GD is characterized by lymphocytic infiltration of the thyroid gland and production of thyrotropin-receptor autoantibodies (TRAbs), leading to hyperthyroidism (20). TRAb, which is found in >95% of newly diagnosed GD patients (21), has been shown to be the main contributor to the onset and maintenance of GD. The incidence rates of GD have increased significantly and are roughly 29–30/100,000 annually in Caucasians (22), while an incidence of 14/100,000 has been reported in China (23). The seasonal trend and the geographical variation in the incidence of GD suggest that infections might be an important contributing factor to the pathogenesis of the disease (20). Twin studies have reported a concordance rate of 35% in monozygotic (MZ) compared to 3% in dizygotic (DZ) twins (reviewed in [24]), and the sibling risk ratio for GD is increased (25), indicating a strong genetic influence on the development of the disease.

GD was initially found to be associated with the HLA-B8 allele in Caucasians (24,26). However, subsequent study suggested that the primary susceptibility allele is the DR3 allele (27), with a frequency of approximately 40–55% in GD patients (26). However, because of the pronounced linkage disequilibrium, the exact location on the extended HLA-A1, B8, DR3 haplotype cannot be pinpointed. In addition, the HLA-DQA1*0501 allele was also shown to be associated with GD in Caucasians (28,29), as have non-MHC genes, including cytotoxic T-lymphocyte-associated protein 4 (CTLA4); CD40; protein tyrosine phosphatase, non-receptor type 22 (PTPN22); thyroglobulin and thyroid stimulating hormone receptor (TSHR) (30,31).

An association between GD and IgAD was previously suggested in various case reports (32, 33, 34, 35), and a small screening study showed that IgAD is overrepresented among GD patients (36) (Table 1), although this could not be confirmed by other groups (37, 38, 39).
Table 1

Prevalence of IgAD among GD patients.

Year

Reference

Country

Age (years)

Sample size

IgAD (prevalence)

Criteria (g/L)

1994

37

Finland

NM

52

0

NM

1999

38

Italy

25–69

23

0

NM

1999

39

Italy

19–79

18

0

NM

2005

36

UK

NM

111

3 (1:37)

<0.1–0.6

2011

15

Sweden

NM

841a

14 (1:60)

<0.07

Total

   

1,045b

17 (1:61)b

 

NM, not mentioned.

aTRAb-positive patients.

bSumming up total screened GD patients and IgAD individuals, the prevalence of IgAD is equal to the total number of IgAD individuals divided by the total number of screened GD patients (this also applies to Tables 26).

Table 2

Prevalence of IgAD among SLE patients.

Year

Reference

Country

Age (years)

Sample size

IgAD (prevalence)

Criteria (g/L)

1969

53

USA

NM

87

4 (1:22)

Undetectable

1972

54

Mexico

NM

106

1 (1:106)

Traces

1976

55

USA

NM

114

3 (1:38)

<0.10

1983

56

UK

NM

138

4 (1:35)

<0.05

1985

57

Turkey

9–66

96

3 (1:32)

<0.05

1988

58

France

NM

72

3 (1:24)

<0.10

1990

59

Spain

NM

130

1 (1:130)

<0.05

1991

60

USA

NM

75

3 (1:25)

NM

1997

61

UK

NM

96

5 (1:19)

<0.5

2007

62

USA

Children

77

4 (1:19)

<0.01

   

Adults

152

8 (1:19)

Absent

2010

63

Brazil

Adults

189

11 (1:17)

<0.05

Total

   

1,332

50 (1:27)

 

Present study

  

Sweden

Adults

706

11 (1:64)

<0.07

  

UK

Adults

844

5 (1:111)

<0.07

  

USA

Adults

874

20 (1:41)

<0.07

  

China

Adults

964

8 (1:121)

<0.07

Total

   

3,388

44 (1:77)

 

NM, not mentioned.

Table 3

Prevalence of IgAD among T1D patients.

Year

Reference

Country

Age (years)

Sample size

IgAD (prevalence)

Criteria (g/L)

1978

96

USA

Adults

421

0 (0)

<0.1

   

3–16

366

9 (1:41)

<0.1

1982

216

Canada

8–51

129

2 (1:65)

Undetectable

1983

217

Germany

NM

483

14 (1:35)

NM

1988

94

Italy

2–16

191

7 (1:27)

<0.1

1992

95

USA

15–48

261

1 (1:261)

<0.05

1994

218

UK

Adults

1785

8 (1:223)

NM

1998

219

UK

2–22

167

3 (1:56)

NM

1998

97

Canada

1–18

236

0 (0)

NM

2000

220

Austria

1–22

403

2 (1:202)

NM

2005

98

Italy

18–70

94

0 (0)

<0.9

2005

221

Tunisia

16–60

261

5 (1:52)

<0.8

2010

222

Iran

6–19

300

2 (1:150)

<0.1

Total

   

5,097

53 (1:96)

 

Present study

  

Sweden

Children, adults

1,252

11 (1:114)

<0.07

  

Italy

NM

245

2 (1:122)

<0.07

Total

   

1,497

13 (1:115)

 

NM, not mentioned.

Table 4

Prevalence of IgAD among CD patients.

Year

Reference

Country

Age (years)

Sample size

IgAD (prevalence)

Criteria (g/L)

1992

113

Sweden

20–68

24

4 (1:6)

NM

1997

117

Italy

0–15

688

12 (1:58)

<0.05

1997

114

Ireland

NM

604

14 (1:43)

<0.05

1998

115

Italy

0–15

1,776

46 (1:39)

<0.05

   

18–65

322

8 (1:40)

<0.05

2000

116

Turkey

0–16

104

3 (1:35)

NM

2000

223

Spain

NM

47

5 (1:10)

<0.07

Total

   

3,565

92 (1:39)

 

2006

124

UK

NM

4,698a

35 (1:131)

<0.06

2008

118

Canada

NM

608a

4 (1:152)

<0.05

Present study

 

Sweden

Children, adults

422,225a

2,309 (1:192)

<0.07

Total

   

427,531

2,348 (1:182)

 

NM, not mentioned.

aPatients with suspected CD.

Table 5

Prevalence of IgA deficiency among MG patients.

Year

Reference

Country

Age (years)

Sample size

IgAD (prevalence)

Criteria (g/L)

1972

224

UK

9–46

54

1 (1:54)

2.5 IU/mL

1976

225

USA

Adults

51

0

NM

1976

226

USA

NM

107

0

NM

1976

227

UK

NM

50

1 (1:50)

Undetectable

1992

228

France

Adults

333

1 (1:333)

0.05

2011

229

Sweden

Adults

512

2 (1:256)

<0.07

Total

   

1,107

5 (1:221)

 

NM, not mentioned.

Table 6

Prevalence of IgA deficiency among JRA and RA patients.

Year

Reference

Country

Age (years)

Sample size

IgAD (prevalence)

Criteria (g/L)

1970

229

USA

2.5–25

200

2 (1:100)

Undetectable

1972

230

USA

Children

176

3 (1:59)

0.2

1973

231

Finland

2–16

115

5 (1:23)

Undetectable

1973

232

USA

1–21

200

8 (1:25)

0.005

1977

233

USA

Children

324

14 (1:23)

0.01

1979

234

UK

Children

582

12 (1:49)

0.1

1983

235

Finland

Children

350

10 (1:35)

0.02

2011

236

Iran

Children

83

1 (1:83)

NM

Total for JRA

   

2,030

55 (1:37)

 

1969

53

USA

NM

61

1 (1:61)

Undetectable

1971

237

Norway

NM

3187

8 (1:398)

Undetectable

1985

57

Turkey

NM

25

1 (1:25)

NM

1997

238

India

1–70

69

1 (1:69)

Undetectable

2003

239

UK

18–75

352

8 (1:44)

<50 IU/mL

Total for RA

   

3,694

19 (1:194)

 

Total

   

5,724

74 (1:77)

 

NM, not mentioned.

We recently investigated the association of IgAD with GD, defined by elevated serum levels of TRAb, in Icelandic and Swedish patients (15). The data showed a markedly higher prevalence of IgAD in the Swedish cohort (see Table 1). Furthermore, the prevalence of TRAb positivity in IgAD patients was increased in both cohorts (1:60, P = 0.006), suggesting a significant association of IgAD with GD. In addition, of the five GD patients with IgAD where DNA could be obtained, four carried the HLA-DR3, DQ2 haplotype (15).

IgAD and Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that is characterized by a diverse array of autoantibodies, immune complex deposition, complement activation and tissue injury, influenced by multiple genetic and environmental factors. It predominantly affects women (prevalence ratio of women to men is 9:1), particularly during the child-bearing years (40). The prevalence of SLE varies among different ethnic groups, ranging from 7 to 71 cases per 100,000 people of European descent (68/100,000 in Sweden [41]), 31 to 70 cases per 100,000 people among Chinese populations (40) and >200 per 100,000 people of African descent (42). The concordance rates within pairs of MZ twins range from 20% to 40% compared with 2% to 5% for DZ twins (43,44). Furthermore, the risk of SLE is increased both in first- and second-degree relatives (43,44), suggesting a strong genetic basis of the disease.

An association with the HLA-DR region, in particular, the HLA-DRB1*0301 and HLA-DRB1*1501 alleles (12,45,46), was reported in SLE patients of European ancestry, whereas DR2 (DRB1*1501) was overrepresented among Asian patients (47, 48, 49). Genes within the class III region of the MHC, including mutS homolog 5 (MSH5) (50) and superkiller viralicidic activity 2-like (SKIV2L) (51), have also been suggested to constitute risk factors for the disease. Furthermore, SLE is associated with a variety of non-MHC genes, including three prime repair exonuclease 1 (TREX1); tumor necrosis factor, alpha-induced protein 3 (TNFAIP3); interferon regulatory factor 5 (IRF5); integrin, alpha M (ITGAM); signal transducer and activator of transcription 4 (STAT4); B lymphoid tyrosine kinase (BLK); B-cell scaffold protein with ankyrin repeats 1 (BANK1); PTPN22; tumor necrosis factor superfamily, member 4 (TNFSF4); PX domain containing serine/threonine kinase (PXK) and interleukin-1 receptor-associated kinase 1 (IRAK1) (reviewed in [52]).

Previous studies have reported an increased frequency of IgAD among SLE patients, ranging from 1:19 in the USA to 1:130 in Spain (Table 2) (53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63). There have also been several case reports on the association between IgAD and SLE (64, 65, 66, 67, 68, 69, 70, 71, 72). However, the total number of patients screened for IgAD is still quite limited, and the criteria used to define IgAD have been variable. We thus determined the frequency of IgAD among 3388 SLE patients in Sweden, the UK, the USA and China, using an enzyme-linked immunosorbent assay to measure the serum IgA levels (for protocol, see [5]). IgAD was identified in a total of 44 patients, giving a total frequency of 1:67 in Caucasians and 1:121 in Chinese (see Table 2). Interestingly, the prevalence of IgAD among the Chinese SLE patients was >30-fold higher than in the general Chinese population (1:4,146) (73), indicating a strong association between these two diseases regardless of ethnic origin (P < 2 × 1016).

Available samples of SLE patients with IgAD were genotyped at the HLA-B, -DR and -DQ loci using a sequence-specific primed polymerase chain reaction (PCR-SSP) (Olerup SSP, Saltjöbaden, Sweden). All Swedish SLE patients with IgAD (n = 6) carried the HLA-B8, DR3, DQ2 haplo-type in a heterozygous form. Of the five English SLE patients, one patient was homozygous for the HLA-B8, DR3, DQ2 haplotype and one was homozygous for the DR3 allele. However, the HLA alleles of Chinese SLE patients did not conform to the known Caucasian risk alleles either for IgAD or SLE.

IgAD and Type 1 Diabetes

Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by destruction of insulin-producing β cells in the pancreas, leading to reduced/absent insulin production. The damage is primarily due to a cell-mediated response, effectuated by activated cytotoxic T cells (CD8+). T1D affects approximately 0.4% of people of European origin (74), but the incidence rate varies greatly between different parts of the world, ranging from 0.6 cases per 100,000 per year in Korea (75) to 40.2 cases per 100,000 per year in selected regions in Finland (76). Furthermore, the incidence of T1D is rising at a rate of 3–5% per year (77,78). Both genetic and environmental factors, including infections, socioeconomic status and nutrition (79, 80, 81), influence the development of the disorder. The concordance rate for T1D in MZ twins is approximately 50% (82, 83, 84, 85), and in a recently published, prospective, long-term follow-up study of MZ twins, a cumulative incidence of 65% was reported (86). Furthermore, the prevalence of T1D in first-degree relatives is markedly higher than in the general population (87,88). Taken together, these studies suggest that the genetic predisposition may be even more important than previously recognized for the development of T1D.

It is commonly accepted that the MHC class II locus is the most important determinant for T1D (89). The predisposing MHC class II haplotypes, DRB1*0301-DQB1*0201 (dR3, DQ2) and DRB1*0401-DQB1*0302 (DR4, DQ8), are present in at least 90% of cases (90). Other susceptibility genes/regions within the MHC region have also been suggested, including the class I HLA-A and -B regions (91), the class II HLA-DRA and -DPB1 regions (91) and notch 4 (NOTCH4) and MSH5 in the class III region (92). Furthermore, a variety of non-MHC region genes have been previously shown to be associated with T1D, including insulin (INS); (CTLA4); (PTPN22); interleukin 2 receptor alpha (IL2RA); SH2B adaptor protein 3 (SH2B3); CLEC16A; IFIH1 and protein tyrosine phosphatase, non-receptor type 2 (PTPN2) (reviewed in [93]).

The prevalence of IgAD in T1D has been reported to range from 1:27 (94) to 1:261 (95) in several reports, although no cases were observed in three studies (96, 97, 98) (Table 3), indicating an increased frequency compared to the general population. We measured IgA serum levels in three separate cohorts of T1D patients (children and adults) in Italy and Sweden. Our own data show a prevalence of IgAD of 1:114 in Sweden and 1:122 in Italy (see Table 3), giving an overall prevalence of 1:100 in Caucasians (a roughly fivefold increase compared to the general population). Of the 11 Swedish T1D patients with concomitant IgAD, 3 were homozygous for the HLA-B8, DR3, DQ2 haplotype; 7 carried a copy of the B8, DR3, DQ2 haplotype; and 1 patient carried a copy of the B18, DR3, DQ2 haplotype. None of the two Italian T1D patients with IgAD carried the DR3, DQ2 haplotype.

IgAD and Celiac Disease

Celiac disease (CD) is a chronic inflammatory disorder of the intestinal tract, characterized by villous atrophy, crypt hyperplasia and inflammation in the small bowel. The disease is due to an immune reaction against gluten and related proteins found in wheat, rye and barley. The damage is mainly caused by intestinal intraepithelial lymphocyte-mediated cytotoxicity, and, already in 1975, Ferguson et al. reported that a local cellmediated immunity reaction to gluten causes villous atrophy (99). The prevalence of CD among adults and children is approximately 1% (100, 101, 102, 103, 104). The disease is recognized in almost the entire world. The Saharawi population in Algeria has the highest prevalence (5.6%) (105), and CD appears to be rare in individuals of Japanese and Chinese ancestry (106). In Europe, the highest prevalence was reported in Finland (2.4%) and the lowest in Germany (0.3%) (107). These differences might be explained by genetic, environmental and social factors. Genetic factors play a key role in the development of CD, as shown by familial aggregation (5–15%) and a high concordance rate in MZ twins (83–86%) compared to DZ twins (17–20%) (108,109).

CD is strongly associated with genes within the MHC class II region, as almost all patients carry HLA-DQ2 and/or -DQ8. The HLA-DQ2 allele, which shows the strongest association with CD, is often encoded together with HLA-B8 and HLA-DR3 on the ancestral 8.1 haplotype. HLA-DQ2 is present in 20–30% of the general population but only 1–3% of all individuals carrying HLA-DQ2 develop CD (110). HLA-DQ8 is present in approximately 18.7% of the general population; however, only 0.1–0.3% of individuals carrying this allele develop CD. Thus, presence of HLA-DQ2 or HLA-DQ8 is a necessary, but not sufficient, prerequisite for developing the disease (111). Non-HLA genes, including regulator of G-protein signaling 1 (RGS1); toll-like receptor 7/8 (TLR7/TLR8); chemokine (C-C motif) receptor 4 (CCR4); parkinson protein 7 (PARK7); runt-related transcription factor 3 (RUNX3); nuclear factor I/A (NFIA); T-cell activation RhoGTPase activating protein (TAGAP) and CD80, were also reported to be specifically involved in CD (112), whereas genetic loci shared with other autoimmune diseases include SH2B3; IRF4; v-rel reticuloendotheliosis viral oncogene homolog (REL); PTPN2; zinc finger, MIZ-type containing 1 (ZMIZ1) and CTLA4 (reviewed in [112]).

IgAD was previously shown to be associated with CD (113, 114, 115, 116, 117, 118), with a reported overall prevalence of 1:39 (Table 4), indicating a 5- to 15-fold increase in the prevalence of IgAD among both children and adults with CD. Conversely, several studies have also shown an increased prevalence of CD among IgAD patients (119, 120, 121, 122, 123). Furthermore, two studies demonstrated a higher prevalence of IgAD among patients with suspected CD (118,124).

We recently investigated the association between IgAD and CD in 442,225 individuals in Sweden, referred to immunology centers between 1998 and 2010because of suspected CD. The patients were screened for antiendomysium and/or anti-gliadin and anti-transglutaminase (TTG) antibodies, and total serum IgA levels were measured at the time of the investigation.

The frequency of positive anti-TTG samples among the IgA-sufficient patients tested in our own clinic (IgA anti-TTG) during the period 2006–2011 was 1.9% (351 out of 18,811 samples from unique patients). However, the diagnostic accuracy varies during the time period, with 3.6% of positive samples in 2011(120 out of 3,321 samples from unique patients). Because there is a high degree of concordance between IgA and IgG anti-TTG levels (125, 126, 127), the positive samples observed above would also be expected to be positive for IgG anti-TTG antibodies. In IgAD patients, IgG anti-TTG, rather than IgA anti-TTG, serves as a marker for CD with a high sensitivity and specificity (128). The prevalence of IgG anti-TTG among IgAD blood donors ranges from 8.7% to 9.8% (123,128), with the prevalence of 9.3% in our own IgAD blood donor cohort (n = 43). However, among patients with IgAD, referred for anti-TTG screening due to gastrointestinal symptoms, the frequency of positive samples was markedly higher (16.6 %) (61 out of 367 samples from unique patients).

Altogether, 971 children and 1,338 adults with IgAD were identified, giving a frequency of 1:192. Of the hitherto resampled 394 individuals, 92% were shown to have IgAD, and the remaining cases were found to have additional antibody defects (common variable immunodeficiency). CD was confirmed in 58 of the 86 IgAD cases that were biopsied, whereas 28 were negative. A total of 46 of the former patients were HLA typed and 40 of them carried one copy of the DQ2 allele (87%), whereas the remaining carried one copy of DQ3 (a broad specificity including DQ8), suggesting that CD patients with IgAD have a similar HLA-DQ distribution as IgA-sufficient CD patients.

IgAD and Myasthenia Gravis

Myasthenia gravis (MG) is an antibody-mediated disorder where autoantibodies against the acetylcholine receptor (anti-AChR antibodies) disrupt normal signal transduction across the neuromuscular junction in the vast majority of cases (129). Anti-MuSK (muscle-specific kinase) antibodies may also be detected in patients without anti-AChR (130). The loss of muscle receptors and the resulting reduction of signal transduction from nerve cells to muscle cells cause muscle weakness. Several autoimmune disorders, such as SLE (131, 132, 133), RA (134), and GD (134, 135, 136, 137), have previously been shown to be overrepresented among patients with MG. The prevalence of MG is approximately 10 per 100,000 in European populations (14.1/100,000 in Sweden [138]) and an incidence of 0.3–3 cases per 100,000 per year (139). The rate of concordance is approximately 35% in MZ and 4–5% in DZ twins (140), indicating a strong genetic component.

The MHC region is reported to be associated with MG (17,141,142). Early-onset MG and patients exhibiting thymic hyperplasia are most strongly associated with the HLA-B8, DR3 haplotype, and late-onset MG is associated with B7 and DR2 alleles (143,144). Non-MHC genes are also known to be associated with MG, including interleukin (IL)-1; CTLA4; IL-10, tumor necrosis factor (TNF)-α; cholinergic receptor, nicotinic, alpha 1 (CHRNA-1) and PTPN22 (reviewed in [145]).

Studies on the frequency of IgAD in cohorts of patients with MG are presented in Table 5. The prevalence of IgAD is slightly elevated from the background rate, although two separate UK reports with 1 IgAD patient in 50 and 54 individuals, respectively, account for a large proportion of the increase. In another study (n = 333), the frequency of IgAD was not significantly increased, with only one patient being IgAD.

We recently investigated the prevalence of IgAD in 512 Swedish MG patients by measuring serum IgA levels using nephelometry. Two IgAD individuals were identified (P = 0.19) (14). Combined with previous studies, 5 of 1,107 MG patients screened were classified as IgAD (1:221). Despite a strong overlap of the HLA-B8, DR3, DQ2 haplotype, the prevalence of IgAD is thus not markedly increased in MG patients.

IgAD and RA

RA is a chronic inflammation, mainly of the synovial joints. Diagnosis is made for patients exhibiting 6 of 10 criteria of the ACR/EULAR Rheumatoid Arthritis Classification Criterion (146). Many patients exhibit increased levels of rheumatoid factor and antibodies against cyclic citrullinated protein. Juvenile rheumatoid arthritis (JRA), also termed juvenile idiopathic arthritis, typically appears from 6 months to 16 years of age (147). The condition in children appears to differ from that in adults, although definitive causes for each, and possible common mechanisms, are poorly understood. The prevalence of RA is approximately 1% worldwide (148), whereas JRA has a lower prevalence among European populations, reportedly between 0.04% in Spain (149) and 0.1% in Finland (150) and other European/North American populations (151). Concordance rates have been reported to be 15.4% in MZ twins and 3.6% in DZ twins (152), reflecting a genetic component that appears to require strong environmental factors for disease development, where the strongest single risk factor is smoking (153).

The HLA-DR4 allele has been shown to be the strongest genetic risk factor for RA (154). The B27 (155,156) and DR1 (154) alleles also appear to constitute risk alleles for RA development. Furthermore, there are suggestions that genes within the B8, DR3 haplotype also contribute to susceptibility to RA (18,155, 57–159), including JRA (156). Other risk alleles for JRA include the DR5 (160), DR8 (161) and B35 (161) alleles, whereas the DR15 and DR4 alleles have been shown to be protective (161,162). In addition to the HLA locus, over 30 genetic loci have been associated with risk for RA, many of which have been identified in recent years. RA was initially reported to be associated with PTPN22 in Caucasians (163) and peptidyl arginine deiminase, type IV (PADI4) in Asian patients (164). Other genes found to be associated with RA by GWAS include tumor necrosis factor receptor-associated factor 1 and encoding complement component 5 (TRAF1-C5); STAT4; TNFAIP3; IL2-IL21; CD40; IL2RA; protein tyrosine phosphatase, receptor type, C (PTPRC) and IRF5 (reviewed in [165]), where CTLA4 was associated with both RA and JRA (166). Other genes associated with JRA include TNFα, macrophage migration inhibitory factor (MIF) and IL-6 (reviewed in [167]).

Studies on RA and JRA contain a total of 5,724 individuals, of whom 74 were IgAD (1:77). In JRA, 55 of 2,030 patients were IgAD (1:37), whereas in RA, 19 of 3,694 patients were IgAD (1:194) (Table 6). It is therefore likely that the increase in IgAD in rheumatic diseases is accountable to large increases in its frequency in JRA, with only a trend for a higher prevalence in RA patients.

Discussion

A common genetic background for selected autoimmune disorders, such as GD, SLE, T1D, CD and potentially MG and RA, involving both MHC and non-MHC encoded genes, has previously been suggested (14,168). There is also a considerable overlap in concomitant diseases; for example, T1D is prevalent in patients with GD, SLE, CD and RA. Furthermore, CD is overrepresented in patients with GD (168), and patients with SLE also show a higher prevalence of thyroid disorders (169,170). In this report, we have added IgAD to this group of diseases, since it shows a markedly increased prevalence in GD, SLE, T1D and CD (Table 7).
Table 7

Overlap between immune-mediated diseases.

 

IgAD

GD

SLE

T1D

CD

IgAD in patients with

1.6%

1.3–3.8%

0.9–1.1%

2.6%

GD in patients with

11.8%

0.5%

0–24%

5%

SLE in patients with

ND

0.5–2.9%

0.6%

2.4%

T1D in patients with

2.8%

1.1–15%

11.6%

5%

CD in patients with

7.7–8.7%

0.9–5.4%

2.4%

4–9%

ND, not determined.

IgAD is thought to be present from birth in most cases. Theoretically, the increased frequency of infections associated with IgAD could therefore precipitate autoimmune disorders such as GD and SLE. However, in CD, IgAD has occasionally been reported to occur after the onset of the gastrointestinal symptoms. Thus, the common genetic background is likely to be the main contributor to the different autoimmune disorders where environmental factors determine if, and when, the primary and subsequent diseases will appear.

The gene(s) involved are primarily located within the MHC region, where the population-attributable risk is strong in T1D, CD and RA and moderate in GD and SLE (168). Our recent preliminary work in IgAD, based on 100 multicase families, suggests a similarly strong MHC-associated risk in these patients. However, owing to strong linkage disequilibrium within the MHC region, the gene(s) involved in disease pathogenesis, with the possible exception of HLA-DQ in CD, have not yet been identified.

It is well documented that IgAD is strongly associated with the MHC region, in particular, the HLA-B8, DR3, DQ2 haplotype (9). This haplotype is also associated with GD, SLE, T1D and CD (reviewed in [16,171]). Although single loci within the MHC region were initially thought to confer susceptibility or resistance to different autoimmune diseases, the current picture is markedly more complex, since multiple loci/genes have been shown to confer independent risk both in SLE (12,51,172) and T1D (91,92,173,174) (Figure 1). This also appears to be true for IgAD where genes both within the class II (9,175) and class III region (176, 177, 178) have been shown to be associated with the defect (Figure 1). Multiple loci have also been suggested to be involved in MG (17), another 8.1 haplotype-associated disease, as well as immune-mediated diseases associated with other HLA haplotypes, including multiple sclerosis (MS) (179) and RA (18,159,175,180).
Figure 1

Markers across the HLA region associated with risk and protection to IgAD and selected autoimmune disorders. The HLA-DRB1*1501 allele constitutes a risk factor for SLE, but is a protective factor for IgAD and T1D.

Case-control studies in European SLE patients have shown a consistent association with the HLA-DRB1*1501 allele and its linked haplotypes (45,46). An association with the DRB1*1501 allele (rs3135391 serving as a tagging SNP) has also been observed in patients with MS (12). Although a few case reports on IgAD in MS patients have been published, no large-scale screening studies have been performed to date. In view of the almost complete protection against IgAD by the DRB1*1501 allele (12), its frequency among MS patients would be expected to be quite low. Similarly, the DRB1*1501-DQB1*0602 haplotype confers protection from T1D (181). Thus, the same allele confers risk or protection in different immune-mediated diseases, suggesting its involvement at a crucial step in pathogenesis.

The association between a given disease and the MHC could either be due to coding mutations/variations in a given gene, directly influencing its function, or, alternatively, mutations/variations in regulatory sequences, affecting the expression of the gene. Examples of the former include copy number variation of functional C4 alleles in SLE (46) and potentially IgAD (182) and promoter polymorphisms in nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 1 (NFKBIL1, also known as IKBL) (183), DEAD (Asp-Glu-Ala-Asp) box polypeptide 39B (DDX39B, also known as BAT1) (184) and HLA-DQA1 (185) in the latter.

We previously suggested that an IgAD predisposing (mutated/variant) haplotype (B8, DR3, DQ2) is present at a frequency of 0.46% in the general Swedish population (10). Preliminary experiments have indeed shown multiple sequence differences between patients and controls homozygous for the 8.1 haplotype. Similar findings have previously been reported by Yan et al. (186) in Alaskan natives with RA, where multiple mutations/variations were identified in the disease-associated haplotype. The presence of such a predisposing haplotype may explain the overlap in HLA between IgAD and autoimmunity, since the affected variant of the 8.1 haplotype might constitute a risk factor for developing additional disorders, including GD, SLE, T1D, CD and potentially MG and RA. However, additional studies in cohorts of patients with different autoimmune diseases will be necessary to substantiate this notion, and full sequencing of the MHC region of the 8.1 haplotype may ultimately be required to identify the potential mutations/variants involved.

The mechanism underlying the induction of IgAD still remains elusive. It is however likely that the pathophysiological process involves a break of tolerance against IgA itself (since 30% of IgAD patients have demonstrable titers of IgG antibodies against IgA) or one of the factors involved in the switching process (such as a proliferation-inducing ligand [APRIL] or B-cell activating factor [BAFF]).

A number of non-MHC genes have also been shown to be associated with GD, SLE, T1D and CD. These genes generally cluster into pathways involved in T-cell differentiation, cell activation/signaling and innate immunity and have been shown to be associated with single or several diseases (Table 8). It is however noteworthy that there is also a lack of association of given “autoimmune” genes such as PTPN22, which shows association with a large number of diseases, including some of the above disorders, suggesting differences in the pathophysiological pathways.
Table 8

SNPs reported to be associated with IgAD and selected autoimmune disorders.a

   

IgAD

GD

SLE

T1D

CD

   

OR

 

OR

 

OR

 

OR

 

OR

 

Locus

Gene

SNP

(95% CI)

Pvalue

(95% CI)

P value

(95% CI)

P value

(95% CI)

P value

(95% CI)

P value

1p13

PTPN22

rs2476601

    

1.35 (1.24–1.47)

Open image in new window

2.04 (1.81–2.29)

Open image in new window

  

1q25.3

NMNAT2

rs2022013

    

0.85 (0.79–0.90)

Open image in new window

    

1q31.2

RGS1

rs2816316

      

0.89 (0.84–0.95)

Open image in new window

0.80 (0.76–0.84)

Open image in new window

2q12.1

ILWRAP

rs917997

        

1.19 (1.14–1.25)

Open image in new window

2q24

IFIH1

rs1990760

0.67 (0.59–0.76)

Open image in new window

  

1.17 (—)

Open image in new window

0.85 (0.81–0.90)

Open image in new window

  

2q32.2

STAT4

rs7574865

    

1.57 (1.49–1.69)

Open image in new window

    

2q33.2

CTLA4

3 SNPs

  

1.49 (1.34–1.66)

Open image in new window

  

0.85 (0.78–0.92)

Open image in new window

1.14 (1.09–1.19)

Open image in new window

3p14.3

PXK

rs6445975

    

1.25 (1.16–1.35)

Open image in new window

    

3p21

CCR1/CCR3

2 SNPs

        

1.30 (1.23–1.39)

Open image in new window

3q25.33

IL21A

rsl 7810546

      

1.09 (1.04–1.14)

Open image in new window

1.36 (1.29–1.44)

Open image in new window

3q28

LPP

rsl 464510

        

1.29 (1.25–1.34)

Open image in new window

4q27

IL2–IL21

2 SNPs

  

0.87 (0.79–0.95)

Open image in new window

  

1.27 (1.15–1.39)

Open image in new window

0.74 (0.70–0.78)

Open image in new window

5p13

IL7R

rs6897932

      

0.89 (0.84–0.94)

Open image in new window

  

6p21.32

HLA

Multi-SNPs

2.53(2.17–2.95)

Open image in new window

4.6 (—)

Open image in new window

2.36 (2.11–2.64)

Open image in new window

6.85 (—)

Open image in new window

6.23 (5.95–6.52)

Open image in new window

6q21

ATG5

rs573775

    

1.19 (1.12–1.27)

Open image in new window

    

6q23.3

TNFAIP3

3 SNPs

    

1.17(1.10–1.25)

Open image in new window

0.90 (0.86–0.95)

Open image in new window

1.23 (1.17–1.28)

Open image in new window

6q25.3

TAGAP

rs1738074

      

0.92 (0.88–0.96)

Open image in new window

1.16 (1.12–1.21)

Open image in new window

7p21.3

ICA1

rs10156091

    

1.32(1.19–1.47)

Open image in new window

    

7q32

IRF5

rs2070197

    

1.88 (1.78–1.95)

Open image in new window

    

8p23.1

BLK

rs2736340

    

1.35 (1.27–1.43)

Open image in new window

    

8q12

LYN

2 SNPs

    

0.77 (0.70–0.84)

Open image in new window

    

10p11

NRP1

rs2666236

      

1.21 (1.11–1.31)

Open image in new window

  

11p15.5

KIAA1542

rs4963128

    

0.78 (0.71–0.85)

Open image in new window

    

11p15.5

INS

187111341

      

1.25(1.15–1.35)

Open image in new window

  

12q13.2

ERBB3

rs2292239

      

1.28(1.21–1.35)

Open image in new window

  

12q24

SH2B3

rs653178

      

1.28 (1.22–1.35)

Open image in new window

1.20 (1.15–1.24)

Open image in new window

1óp11.2

ITGAM

3 SNPs

    

1.62 (1.47–1.78)

Open image in new window

    

16p13.13

CLEC16A

3 SNPs

0.64 (0.54–0.77)

Open image in new window

  

1.16 (—)

Open image in new window

0.81 (0.77–0.86)

Open image in new window

0.86 (0.82–0.91)

Open image in new window

18p11.21

PTPN2

2 SNPs

      

1.30 (1.22–1.40)

Open image in new window

1.17 (1.12–1.23)

Open image in new window

18q22.2

CD226

rs763361

      

1.16(1.10–1.22)

Open image in new window

  

22q11.21

UBE2L3

2 SNPs

    

1.22 (1.14–1.32)

Open image in new window

  

1.13(1.08–1.19)

Open image in new window

22q13.2

SCUBEI

rs2071725

    

0.78 (0.72–0.86)

Open image in new window

    

aColor-code from dark red to green represents the strong and weak association, respectively:

5E-32~lower Open image in new window

5E-26~5E-32 Open image in new window

5E-20~5E-26 Open image in new window

5E-14~5E-20 Open image in new window

5E-08~5E-14 Open image in new window

5E-08~higher Open image in new window .

IFIH1 is located on chromosome 2q24 and encodes the interferon induced with helicase C domain 1 protein. Together with retinoic acid-inducible gene I (RIG-1), it functions as a sensor for viral infections. IFIH1 expression is highly upregulated in activated immune cells in response to type 1 interferon induced by viral infections, suggesting that it could potentially be involved in the pathogenesis of autoimmune diseases including T1D (187). Several SNPs within the IFIH1 gene and its 3′ untranslated region show an association with T1D (rs2111485, rs13422767, rs1990760 and rs3747517) (188), where the rs1990760 marker (Ala946Thr) is the most strongly associated (reviewed in [189]). Most of these rare IFIH1 alleles are protective against disease (190).

A recent large-scale study also showed a highly significant association of rs1990760 to SLE in Caucasian (191) but not in Japanese patients (192). Moreover, GD has also been shown to be associated with rs1990760 (193), although this point remains controversial (194, 195, 196). CD, on the other hand, does not appear to be associated with rs1990760 (74).

In 2010, we performed a GWAS on a large cohort of patients with IgAD (13) and identified an association with rs1990760 in the IFIH1 gene. Taken together, there is thus ample evidence for the implication of IFIH1 both in IgAD and in several autoimmune disorders, although the mechanism involved remains elusive.

CLEC16A, located on chromosome 16p13, is widely expressed on B lymphocytes, natural killer and dendritic cells (197). Several SNPs (rs2903692, rs17673553, rs725613 and rs12708716) within the CLEC16A gene have been shown to be associated with T1D in different populations (196,198, 199, 200, 201, 202, 203). Dubois et al. (204) recently also identified an association between the class II, major histocompatibility complex, transactivator (CIITA)-suppressor of cytokine signaling 1 (SOCS1)-CLEC16A region and CD, although it just reached borderline genome-wide significance. Another study, however, suggested that CLEC16A (rs2903692) is not involved in susceptibility to CD development (205). rs12708716 was also suggested to be associated with SLE (191) where the A allele confers susceptibility. Awata et al., on the other hand, showed that rs2903692 was not associated with GD in Japanese patients (206). In IgAD, we recently showed suggestive evidence for association with CLEC16A (rs6498142 and rs7201845) (13), again suggesting a common genetic link.

One remaining question is whether the MHC- and non-MHC-associated susceptibility genes are acting independently or synergistically in the pathophysiological processes underlying autoimmune diseases. A number of studies have addressed this question, and Hodge et al. (207) and Jacobson et al. (25) showed that interaction between HLA-DRB1*03 and different thyroglobulin variants conferred an increased risk for GD. A subsequent study in Japanese subjects (208) suggested that there was also an interaction between selected HLA-A and DP alleles and CTLA4 in a subgroup of GD patients, although Kula et al. (209) suggested that the interaction with CTLA4 was due to HLA-DR encoding genes.

In T1D, a study in Belgian patients showed no interaction between HLA-DQ and the IFIH1 rs1990760 SNP (210). However, PTPN22 Trp620 (rs2476601) has a higher relative risk in T1D patients carrying low-risk MHC class II genotypes (non-DR3/DR4) than in those carrying the high-risk ones, suggesting a potential interaction (211, 212, 213). Moreover, a Norwegian study indicated a weak synergistic effect between FOXP3 and the HLA-DR3, DQ2, haplotype both in T1D and CD patients (214). A recent case-control collection study also showed a significant interaction between HLA-DR3 and IRF5 in patients with SLE (215). Similar interaction studies in IgAD have not yet been performed.

In summary, IgAD is markedly more prevalent in patients with a variety, albeit not all (such as MG [14]), of 8.1 hap-lotype-associated autoimmune diseases. Similarities in the genetic susceptibility suggest involvement of common pathophysiological pathways, implicating that IgAD, as recently suggested by Ferreira et al. (13), may in fact be an autoimmune disease. However, additional dense SNPing and sequencing of the implicated genes may be required to fully understand the mechanisms involved.

Disclosure

TW Behrens is a full-time employee of Genentech.

Notes

Acknowledgments

This work was supported by the Swedish Research Council, the European Union-funded project EURO-PADnet (grant 201 549) and the KI funding for PhD students program for PhD students at the Karolinska Institutet (N Wang). We are indebted to Francesco Cucca at the University of Sassari, Italy, for providing samples from Italian patients with T1D and Magdalena Janzi and Ryan Ramanujam for their contributions in the early stages of this work.

References

  1. 1.
    Pan-Hammarström Q, Hammarström L (2008) Antibody deficiency diseases. Eur. J. Immunol. 38:327–33.PubMedCrossRefGoogle Scholar
  2. 2.
    Pereira LF, et al. (1997) Prevalence of selective IgA deficiency in Spain: more than we thought. Blood. 90:893.PubMedGoogle Scholar
  3. 3.
    Kanoh T, et al. (1986) Selective IgA deficiency in Japanese blood donors: frequency and statistical analysis. Vox Sang. 50:81–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Weber-Mzell D, et al. (2004) Gender, age and seasonal effects on IgA deficiency: a study of 7293 Caucasians. Eur. J. Clin. Invest. 34:224–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Janzi M, et al. (2009) Selective IgA deficiency in early life: association to infections and allergic diseases during childhood. Clin. Immunol. 133:78–85.PubMedCrossRefGoogle Scholar
  6. 6.
    Notarangelo LD, et al. (2009) Primary immunodeficiencies: 2009 update. J. Allergy Clin. Immunol. 124:1161–78.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Latiff AHA, Kerr MA. (2007) The clinical significance of immunoglobulin A deficiency. Ann. Clin. Biochem. 44:131–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Cunningham-Rundles C, Fotino M, Rosina O, Peter JB. (1991) Selective IgA deficiency, IgG subclass deficiency, and the major histocompatibility complex. Clin. Immunol. Immunopathol. 61:S61–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Olerup O, Smith CI, Hammarström L. (1990) Different amino acids at position 57 of the HLA-DQ beta chain associated with susceptibility and resistance to IgA deficiency. Nature. 347:289–90.PubMedCrossRefGoogle Scholar
  10. 10.
    Mohammadi J, et al. (2010) IgA deficiency and the MHC: assessment of relative risk and micro-heterogeneity within the HLA A1 B8, DR3 (8.1) haplotype. J. Clin. Immunol. 30:138–43.PubMedCrossRefGoogle Scholar
  11. 11.
    MacHulla HK, et al. (2000) HLA-A, B, Cw and DRB1, DRB3/4/5, DQB1, DPB1 frequencies in German immunoglobulin A-deficient individuals. Scand. J. Immunol. 52:207–11.PubMedCrossRefGoogle Scholar
  12. 12.
    Goyette P, et al. (2009) Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc. Natl. Acad. Sci. U. S. A. 106:18680–5.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Ferreira RC, et al. (2010) Association of IFIH1 and other autoimmunity risk alleles with selective IgA deficiency. Nat. Genet. 42:777–80.PubMedCrossRefGoogle Scholar
  14. 14.
    Ramanujam R, Piehl F, Pirskanen R, Gregersen PK, Hammarström L. (2011) Concomitant autoimmunity in myasthenia gravis: lack of association with IgA deficiency. J. Neuroimmunol. 236:118–22.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Jorgensen GH, et al. (2011) Association of immunoglobulin A deficiency and elevated thyrotropin-receptor autoantibodies in two Nordic countries. Hum. Immunol. 72:166–72.PubMedCrossRefGoogle Scholar
  16. 16.
    Price P, et al. (1999) The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol. Rev. 167:257–74.PubMedCrossRefGoogle Scholar
  17. 17.
    Vandiedonck C, et al. (2004) Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia. Proc. Natl. Acad. Sci. U. S. A. 101:15464–9.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Jawaheer D, et al. (2002) Dissecting the genetic complexity of the association between human leukocyte antigens and rheumatoid arthritis. Am. J. Hum. Genet. 71:585–94.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Jacobson DL, Gange SJ, Rose NR, Graham NM. (1997) Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84:223–43.PubMedCrossRefGoogle Scholar
  20. 20.
    Prabhakar BS, Bahn RS, Smith TJ. (2003) Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr. Rev. 24:802–35.PubMedCrossRefGoogle Scholar
  21. 21.
    Zöphel K, Roggenbuck D, Schott M. (2010) Clinical review about TRAb assay’s history. Autoimmun. Rev. 9:695–700.PubMedCrossRefGoogle Scholar
  22. 22.
    Lantz M, Abraham-Nordling M, Svensson J, Wallin G, Hallengren B. (2009) Immigration and the incidence of Graves’ thyrotoxicosis, thyrotoxic multinodular goiter and solitary toxic adenoma. Eur. J. Endocrinol. 160:201–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Wong GW, Cheng PS. (2001) Increasing incidence of childhood Graves’ disease in Hong Kong: a follow-up study. Clin. Endocrinol. (Oxf). 54:547–50.PubMedCrossRefGoogle Scholar
  24. 24.
    Tomer Y, Davies TF (2003) Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr. Rev. 24:694–717.PubMedCrossRefGoogle Scholar
  25. 25.
    Jacobson EM, Huber A, Tomer Y. (2008) The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology. J. Autoimmun. 30:58–62.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Farid NR, Stone E, Johnson G. (1980) Graves’ disease and HLA: clinical and epidemiologic associations. Clin. Endocrinol. (Oxf). 13:535–44.PubMedCrossRefGoogle Scholar
  27. 27.
    Zamani M, Spaepen M, Bex M, Bouillon R, Cassiman JJ. (2000) Primary role of the HLA class II DRB1*0301 allele in Graves disease. Am. J. Med. Genet. 95:432–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Yanagawa T, et al. (1993) Human histocompatibility leukocyte antigen-DQA1*0501 allele associated with genetic susceptibility to Graves’ disease in a Caucasian population. J. Clin. Endocrinol. Metab. 76:1569–74.PubMedGoogle Scholar
  29. 29.
    Marga M, Denisova A, Sochnev A, Pirags V, Farid NR. (2001) Two HLA DRB 1 alleles confer independent genetic susceptibility to Graves disease: relevance of cross-population studies. Am. J. Med. Genet. 102:188–91.PubMedCrossRefGoogle Scholar
  30. 30.
    Jacobson EM, Tomer Y. (2007) The genetic basis of thyroid autoimmunity. Thyroid. 17:949–61.PubMedCrossRefGoogle Scholar
  31. 31.
    Tomer Y. (2010) Genetic susceptibility to autoimmune thyroid disease: past, present, and future. Thyroid. 20:715–25.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Pariente EA, et al. (1985) Collagenous colitis, IgA deficiency, Basedow’s disease and atrophic gastritis [in French]. Gastroenterol. Clin. Biol. 9:738–11.PubMedGoogle Scholar
  33. 33.
    Mano T, Kawakubo A, Yamamoto M. (1992) Isolated IgA deficiency accompanied by autoimmune thyroid disease. Intern. Med. 31:1201–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Hoffman WH, Helman SW, Sekul E, Carroll JE, Vega RA. (2003) Lambert-Eaton Myasthenic syndrome in a child with an autoimmune phenotype. Am. J. Med. Genet. A. 119A:77–80.PubMedCrossRefGoogle Scholar
  35. 35.
    Silva JM de A, Silva CP, Melo FF, Silva LAA, Utagawa CY. (2010) Graves disease and IgA deficiency as manifestations of 22q11.2 deletion syndrome [in Portuguese]. Arq. Bras. Endocrinol. Metabol. 54:572–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Ch’ng CL, Biswas M, Benton A, Jones MK, Kingham JGC. (2005) Prospective screening for coeliac disease in patients with Graves’ hyperthyroidism using anti-gliadin and tissue transglutaminase antibodies. Clin. Endocrinol. (Oxf). 62:303–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Collin P, Salmi J, Hällström O, Reunala T, Pasternack A. (1994) Autoimmune thyroid disorders and coeliac disease. Eur. J. Endocrinol. 130:137–40.PubMedCrossRefGoogle Scholar
  38. 38.
    Cuoco L, et al. (1999) Prevalence and early diagnosis of coeliac disease in autoimmune thyroid disorders. Ital. J. Gastroenterol. Hepatol. 31:283–7.PubMedGoogle Scholar
  39. 39.
    Carroccio A, et al. (1999) Evidence of transient IgA anti-endomysial antibody positivity in a patient with Graves’ disease. Digestion. 60:86–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Han J-W, et al. (2009) Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat. Genet. 41:1234–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Ståhl-Hallengren C, Jönsen A, Nived O, Sturfelt G. (2000) Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J. Rheumatol. 27:685–91.PubMedGoogle Scholar
  42. 42.
    Johnson AE, Gordon C, Palmer RG, Bacon PA. (1995) The prevalence and incidence of systemic lupus erythematosus in Birmingham, England: relationship to ethnicity and country of birth. Arthritis Rheum. 38:551–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Alarcón-Segovia D, et al. (2005) Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum. 52:1138–47.PubMedCrossRefGoogle Scholar
  44. 44.
    Deapen D, et al. (1992) A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 35:311–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Tsao BP. (2004) Update on human systemic lupus erythematosus genetics. Curr. Opin. Rheumatol. 16:513–21.PubMedCrossRefGoogle Scholar
  46. 46.
    Yang Y, et al. (2007) Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am. J. Hum. Genet. 80:1037–54.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Hashimoto H, et al. (1985) HLA antigens associated with systemic lupus erythematosus in Japan. J. Rheumatol. 12:919–23.PubMedGoogle Scholar
  48. 48.
    Hirose S, Ogawa S, Nishimura H, Hashimoto H, Shirai T. (1988) Association of HLA-DR2/DR4 heterozygosity with systemic lupus erythematosus in Japanese patients. J. Rheumatol. 15:1489–92.PubMedGoogle Scholar
  49. 49.
    Hong GH, et al. (1994) Association of complement C4 and HLA-DR alleles with systemic lupus erythematosus in Koreans. J. Rheumatol. 21:442–7.PubMedGoogle Scholar
  50. 50.
    Harley JB, et al. (2008) Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 40:204–10.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Fernando MMA, et al. (2007) Identification of two independent risk factors for lupus within the MHC in United Kingdom families. PLoS. Genet. 3:e192.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Harley ITW, Kaufman KM, Langefeld CD, Harley JB, Kelly JA. (2009) Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat. Rev. Genet. 10:285–90.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Cassidy JT, Burt A, Petty R, Sullivan D. (1969) Selective IgA deficiency in connective tissue diseases. N. Engl. J. Med. 280:275.PubMedGoogle Scholar
  54. 54.
    Alarcón-Segovia D, Fishbein E. (1972) Serum immunoglobulins in systemic lupus erythematosus. Clin. Sci. 43:121–31.PubMedCrossRefGoogle Scholar
  55. 55.
    Gershwin ME, Blaese RM, Steinberg AD, Wistar R Jr, Strober W. (1976) Antibodies to nucleic acids in congenital immune deficiency states. J. Pediatr. 89:377–81.PubMedCrossRefGoogle Scholar
  56. 56.
    Yewdall V, et al. (1983) Systemic lupus erythematosus and IgA deficiency. J. Clin. Lab. Immunol. 10:13–8.PubMedGoogle Scholar
  57. 57.
    Kuştimur S, Gülmezoğlu E. (1985) Selective IgA deficiency in patients with systemic lupus erythematosus and rheumatoid arthritis [in Turkish]. Mikrobiyol. Bul. 19:190–9.PubMedGoogle Scholar
  58. 58.
    Rifle G, et al. (1988) Selective IgA deficiency and systemic lupus erythematosus. Ann. Med. Interne. (Paris). 139:134–7.PubMedGoogle Scholar
  59. 59.
    Calabozo Raluy M, Gamir Gamir ML, Medina Luezas J, Diaz-Miguel Pérez C, Alonso Ruiz A. (1990) Selective deficiency of IgA in autoimmune diseases [in Spanish]. Rev. Clin. Esp. 186:163–5.PubMedGoogle Scholar
  60. 60.
    Kaufman LD, Heinicke MH, Hamburger M, Gorevic PD. (1991) Male lupus: prevalence of IgA deficiency, 7S IgM and abnormalities of reticuloendothelial system Fc-receptor function. Clin. Exp. Rheumatol. 9:265–9.PubMedGoogle Scholar
  61. 61.
    Rankin EC, Isenberg DA. (1997) IgA deficiency and SLE: prevalence in a clinic population and a review of the literature. Lupus. 6:390–4.PubMedCrossRefGoogle Scholar
  62. 62.
    Cassidy JT, Kitson RK, Selby CL. (2007) Selective IgA deficiency in children and adults with systemic lupus erythematosus. Lupus. 16:647–50.PubMedCrossRefGoogle Scholar
  63. 63.
    Mantovani APF, Monclaro MP, Skare TL. (2010) Prevalence of IgA deficiency in adult systemic lupus erythematosus and the study of the association with its clinical and autoantibody profiles. Rev. Bras. Reumatol. 50:273–82.PubMedCrossRefGoogle Scholar
  64. 64.
    Bachmann R. (1965) Studies on the serum gamma-A-globulin level. 3. The frequency of A-gamma-A-globulinemia. Scand. J. Clin. Lab. Invest. 17:316–20.PubMedCrossRefGoogle Scholar
  65. 65.
    Claman HN, Merrill DA, Peakman D, Robinson A. (1970) Isolated severe gamma A deficiency: immunoglobulin levels, clinical disorders, and chromosome studies. J. Lab. Clin. Med. 75:307–15.PubMedGoogle Scholar
  66. 66.
    Bach GL, Pillary VK, Kark RM. (1971) Immunoglobulin (IgA) deficiency in systemic lupus erythematosus: report of a case and family studies. Acta. Rheumatol. Scand. 17:63–71.PubMedCrossRefGoogle Scholar
  67. 67.
    Cleland LG, Bell DA. (1978) The occurrence of systemic lupus erythematosus in two kindreds in association with selective IGA deficiency. J. Rheumatol. 5:288–93.PubMedGoogle Scholar
  68. 68.
    Woo P, Pereira RS, Lever AM. (1984) Persistent immunoglobulin deficiency after prednisolone and antiepileptic therapy in a C2 deficient patient with lupus-like syndrome. J. Rheumatol. 11:828–31.PubMedGoogle Scholar
  69. 69.
    Katial RK, Hatch RM, Baker MR. (1994) Cardiac tamponade and recurrent upper respiratory tract infections in a 22-year-old woman. Ann. Allergy. 73:473–7.PubMedGoogle Scholar
  70. 70.
    Arai J, et al. (1998) Non-X-linked hyper-IgM syndrome with systemic lupus erythematosus. Clin. Exp. Rheumatol. 16:84–6.PubMedGoogle Scholar
  71. 71.
    John M, Lam M, Latham B, Saker B, French MA. (2000) Nephrotic syndrome in a patient with IgA deficiency-associated mesangioproliferative glomerulonephritis. Pathology. 32:56–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Desar IME, Weemaes CMR, van Deuren M, van der Meer JWM. (2007) Reversible hypogamma-globulinaemia. Neth. J. Med. 65:381–5.PubMedGoogle Scholar
  73. 73.
    Feng L. (1992) Epidemiological study of selective IgA deficiency among 6 nationalities in China [in Chinese]. Zhonghua. Yi. Xue. Za. Zhi. 72:88–90,128.PubMedGoogle Scholar
  74. 74.
    Smyth DJ, et al. (2008) Shared and distinct genetic variants in type 1 diabetes and celiac disease. N. Engl. J. Med. 359:2767–77.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Karvonen M, Tuomilehto J, Libman I, LaPorte R. (1993) A review of the recent epidemiological data on the worldwide incidence of type 1 (insulin-dependent) diabetes mellitus. World Health Organization DIAMOND Project Group. Diabetologia. 36:883–92.PubMedCrossRefGoogle Scholar
  76. 76.
    EURODIAB ACE Study Group. (2000) Variation and trends in incidence of childhood diabetes in Europe. Lancet. 355:873–6.CrossRefGoogle Scholar
  77. 77.
    Onkamo P, Väänänen S, Karvonen M, Tuomilehto J. (1999) Worldwide increase in incidence of type I diabetes: the analysis of the data on published incidence trends. Diabetologia. 42:1395–403.PubMedCrossRefGoogle Scholar
  78. 78.
    DIAMOND Project Group. (2006) Incidence and trends of childhood type 1 diabetes worldwide 1990–1999. Diabet. Med. 23:857–66.CrossRefGoogle Scholar
  79. 79.
    Virtanen SM, Knip M. (2003) Nutritional risk predictors of beta cell autoimmunity and type 1 diabetes at a young age. Am. J. Clin. Nutr. 78:1053–67.PubMedCrossRefGoogle Scholar
  80. 80.
    Bach J-F. (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med 347:911–20.PubMedCrossRefGoogle Scholar
  81. 81.
    Zipitis CS, Akobeng AK. (2008) Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and metaanalysis. Arch. Dis. Child. 93:512–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Kyvik KO, Green A, Beck-Nielsen H. (1995) Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. BMJ. 311:913–7.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Redondo MJ, et al. (2001) Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia. 44:354–62.PubMedCrossRefGoogle Scholar
  84. 84.
    Hyttinen V, Kaprio J, Kinnunen L, Koskenvuo M, Tuomilehto J. (2003) Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes. 52:1052–5.PubMedCrossRefGoogle Scholar
  85. 85.
    Condon J, et al. (2008) A study of diabetes mellitus within a large sample of Australian twins. Twin Res. Hum. Genet. 11:28–40.PubMedCrossRefGoogle Scholar
  86. 86.
    Redondo MJ, Jeffrey J, Fain PR, Eisenbarth GS, Orban T. (2008) Concordance for islet autoimmunity among monozygotic twins. N. Engl. J. Med 359:2849–50.PubMedCrossRefGoogle Scholar
  87. 87.
    WHO Multinational Project for Childhood Diabetes Group. (1991) Familial insulin-dependent diabetes mellitus (IDDM) epidemiology: standardization of data for the DIAMOND Project. Bull. World Health Organ. 69:767–77.Google Scholar
  88. 88.
    Anaya J-M, et al. (2006) Familial clustering of autoimmune diseases in patients with type 1 diabetes mellitus. J. Autoimmun. 26:208–14.PubMedCrossRefGoogle Scholar
  89. 89.
    Steenkiste A, et al. (2007) 14th International HLA and Immunogenetics Workshop: report on the HLA component of type 1 diabetes. Tissue Antigens. 69 Suppl 1:214–25.PubMedCrossRefGoogle Scholar
  90. 90.
    Noble JA, Valdes AM, Thomson G, Erlich HA. (2000) The HLA class II locus DPB1 can influence susceptibility to type 1 diabetes. Diabetes. 49:121–5.PubMedCrossRefGoogle Scholar
  91. 91.
    Howson JMM, Walker NM, Clayton D, Todd JA. (2009) Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A. Diabetes Obes. Metab. 11Suppl 1:31–45.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Valdes AM, Thomson G. (2009) Several loci in the HLA class III region are associated with T1D risk after adjusting for DRB1-DQB1. Diabetes Obes. Metab. 11 Suppl 1:46–52.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Pociot F, et al. (2010) Genetics of type 1 diabetes: what’s next? Diabetes. 59:1561–71.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Cerutti F, et al. (1988) Selective IgA deficiency in juvenile-onset insulin-dependent diabetes mellitus [in Italian]. Pediatr. Med. Chir. 10:197–201.PubMedGoogle Scholar
  95. 95.
    Liblau RS, Caillat-Zucman S, Fischer AM, Bach JF, Boitard C. (1992) The prevalence of selective IgA deficiency in type 1 diabetes mellitus. APMIS. 100:709–12.PubMedCrossRefGoogle Scholar
  96. 96.
    Smith WI, Rabin BS, Huellmantel A, Van Thiel DH, Drash A. (1978) Immunopathology of juvenile-onset diabetes mellitus. I. IgA deficiency and juvenile diabetes. Diabetes. 27:1092–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Fraser-Reynolds KA, Butzner JD, Stephure DK, Trussell RA, Scott RB. (1998) Use of immunoglobulin A-antiendomysial antibody to screen for celiac disease in North American children with type 1 diabetes. Diabetes Care. 21:1985–9.PubMedCrossRefGoogle Scholar
  98. 98.
    Picarelli A, et al. (2005) Anti-endomysial antibody of IgG1 isotype detection strongly increases the prevalence of coeliac disease in patients affected by type I diabetes mellitus. Clin. Exp. Immunol. 142:111–5.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Ferguson A, MacDonald TT, McClure JP, Holden RJ. (1975) Cell-mediated immunity to gliadin within the small-intestinal mucosa in coeliac disease. Lancet. 1:895–7.PubMedCrossRefGoogle Scholar
  100. 100.
    Bingley PJ, et al. (2004) Undiagnosed coeliac disease at age seven: population based prospective birth cohort study. BMJ. 328:322–3.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Fasano A, et al. (2003) Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch. Intern. Med. 163:286–92.PubMedCrossRefGoogle Scholar
  102. 102.
    Mäki M, et al. (2003) Prevalence of celiac disease among children in Finland. N. Engl. J. Med. 348:2517–24.PubMedCrossRefGoogle Scholar
  103. 103.
    Tatar G, et al. (2004) Screening of tissue transglutaminase antibody in healthy blood donors for celiac disease screening in the Turkish population. Dig. Dis. Sci. 49:1479–84.PubMedCrossRefGoogle Scholar
  104. 104.
    West J, et al. (2003) Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut 52:960–5.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Catassi C, et al. (1999) Why is coeliac disease endemic in the people of the Sahara? Lancet. 354:647–8.PubMedCrossRefGoogle Scholar
  106. 106.
    Cummins AG, Roberts-Thomson IC. (2009) Prevalence of celiac disease in the Asia-Pacific region. J. Gastroenterol. Hepatol. 24:1347–51.PubMedCrossRefGoogle Scholar
  107. 107.
    Mustalahti K, et al. (2010) The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann. Med. 42:587–95.PubMedCrossRefGoogle Scholar
  108. 108.
    Greco L, et al. (2002) The first large population based twin study of coeliac disease. Gut 50:624–8.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Nisticò L, et al. (2006) Concordance, disease progression, and heritability of coeliac disease in Italian twins. Gut 55:803–8.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Liu E, Rewers M, Eisenbarth GS. (2005) Genetic testing: who should do the testing and what is the role of genetic testing in the setting of celiac disease? Gastroenterology. 128:S33–7.PubMedCrossRefGoogle Scholar
  111. 111.
    Petronzelli F, et al. (1997) Genetic contribution of the HLA region to the familial clustering of coeliac disease. Ann. Hum. Genet. 61:307–17.PubMedCrossRefGoogle Scholar
  112. 112.
    Trynka G, Wijmenga C, van Heel DA. (2010) A genetic perspective on coeliac disease. Trends Mol. Med. 16:537–50.PubMedCrossRefGoogle Scholar
  113. 113.
    Lavö B, Knutson F, Knutson L, Sjöberg O, Hällgren R. (1992) Jejunal secretion of secretory immunoglobulins and gliadin antibodies in celiac disease. Dig. Dis. Sci. 37:53–9.PubMedCrossRefGoogle Scholar
  114. 114.
    Heneghan MA, Stevens FM, Cryan EM, Warner RH, McCarthy CF. (1997) Celiac sprue and immunodeficiency states: a 25-year review. J. Clin. Gastroenterol. 25:421–5.PubMedCrossRefGoogle Scholar
  115. 115.
    Cataldo F, Marino V, Ventura A, Bottaro G, Corazza GR. (1998) Prevalence and clinical features of selective immunoglobulin A deficiency in coeliac disease: an Italian multicentre study. Italian Society of Paediatric Gastroenterology and Hepatology (SIGEP) and “Club del Tenue” Working Groups on Coeliac Disease. Gut 42:362–5.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Demir H, Yüce A, Koçak N, Ozen H, Gürakan F. (2000) Celiac disease in Turkish children: presentation of 104 cases. Pediatr. Int. 42:483–7.PubMedCrossRefGoogle Scholar
  117. 117.
    Cataldo F, Marino V, Bottaro G, Greco P, Ventura A. (1997) Celiac disease and selective immunoglobulin A deficiency. J. Pediatr. 131:306–8.PubMedCrossRefGoogle Scholar
  118. 118.
    McGowan KE, Lyon ME, Butzner JD. (2008) Celiac disease and IgA deficiency: complications of serological testing approaches encountered in the clinic. Clin. Chem. 54:1203–9.PubMedCrossRefGoogle Scholar
  119. 119.
    Klemola T. (1987) Deficiency of immunoglobulin A. Ann. Clin. Res. 19:248–57.PubMedGoogle Scholar
  120. 120.
    Collin P, et al. (1992) Selective IgA deficiency and coeliac disease. Scand. J. Gastroenterol. 27:367–71.PubMedCrossRefGoogle Scholar
  121. 121.
    Meini A, et al. (1996) Prevalence and diagnosis of celiac disease in IgA-deficient children. Ann. Allergy Asthma Immunol. 77:333–6.PubMedCrossRefGoogle Scholar
  122. 122.
    Prince HE, Norman GL, Binder WL. (2000) Immunoglobulin A (IgA) deficiency and alternative celiac disease-associated antibodies in sera submitted to a reference laboratory for endomysial IgA testing. Clin. Diagn. Lab. Immunol. 7:192–6.PubMedPubMedCentralGoogle Scholar
  123. 123.
    Lenhardt A, et al. (2004) Role of human-tissue transglutaminase IgG and anti-gliadin IgG antibodies in the diagnosis of coeliac disease in patients with selective immunoglobulin A deficiency. Dig. Liver Dis. 36:730–4.PubMedCrossRefGoogle Scholar
  124. 124.
    Sinclair D, Saas M, Turk A, Goble M, Kerr D. (2006) Do we need to measure total serum IgA to exclude IgA deficiency in coeliac disease? J. Clin. Pathol. 59:736–9.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Bilbao JR, et al. (2002) Immunoglobulin G autoantibodies against tissue-transglutaminase: a sensitive, cost-effective assay for the screening of celiac disease. Autoimmunity. 35:255–9.PubMedGoogle Scholar
  126. 126.
    Martín-Pagola A, et al. (2007) Two-year follow-up of anti-transglutaminase autoantibodies among celiac children on gluten-free diet: comparison of IgG and IgA. Autoimmunity. 40:117–21.PubMedCrossRefGoogle Scholar
  127. 127.
    Bansal AK, Lindemann MJ, Ramsperger V, Kumar V. (2009) Celiac G+ antibody assay for the detection of autoantibodies in celiac disease. Ann. N. Y. Acad. Sci. 1173:36–40.PubMedCrossRefGoogle Scholar
  128. 128.
    Korponay-Szabó IR, et al. (2003) Elevation of IgG antibodies against tissue transglutaminase as a diagnostic tool for coeliac disease in selective IgA deficiency. Gut 52:1567–71.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Drachman DB. (1994) Myasthenia gravis. N. Engl. J. Med. 330:1797–810.PubMedCrossRefGoogle Scholar
  130. 130.
    Hoch W, et al. (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7:365–8.PubMedCrossRefGoogle Scholar
  131. 131.
    Vaiopoulos G, et al. (1994) The association of systemic lupus erythematosus and myasthenia gravis. Postgrad. Med. J. 70:741–5.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Bhinder S, Majithia V, Harisdangkul V. (2006) Myasthenia gravis and systemic lupus erythematosus: truly associated or coincidental: two case reports and review of the literature. Clin. Rheumatol. 25:555–6.PubMedCrossRefGoogle Scholar
  133. 133.
    Hrycek A. (2009) Systemic lupus erythematosus and myasthenia gravis. Pol. Arch. Med. Wewn. 119:582–5.PubMedGoogle Scholar
  134. 134.
    Christensen PB, et al. (1995) Associated autoimmune diseases in myasthenia gravis: a population-based study. Acta. Neurol. Scand. 91:192–5.PubMedCrossRefGoogle Scholar
  135. 135.
    Sahay BM, Blendis LM, Greene R. (1965) Relation between myasthenia gravis and thyroid disease. Br. Med. J. 1:762–5.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Toth C, McDonald D, Oger J, Brownell K. (2006) Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease. Acta. Neurol. Scand. 114:124–32.PubMedCrossRefGoogle Scholar
  137. 137.
    Kanazawa M, Shimohata T, Tanaka K, Nishizawa M. (2007) Clinical features of patients with myasthenia gravis associated with autoimmune diseases. Eur. J. Neurol. 14:1403–4.PubMedCrossRefGoogle Scholar
  138. 138.
    Kalb B, Matell G, Pirskanen R, Lambe M. (2002) Epidemiology of myasthenia gravis: a population-based study in Stockholm, Sweden. Neuroepidemiology. 21:221–5.PubMedCrossRefGoogle Scholar
  139. 139.
    McGrogan A, Sneddon S, de Vries CS. (2010) The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. 34:171–83.PubMedCrossRefGoogle Scholar
  140. 140.
    Ramanujam R, Pirskanen R, Ramanujam S, Hammarström L. (2011) Utilizing twins concordance rates to infer the predisposition to myasthenia gravis. Twin Res. Hum. Genet. 14:129–36.PubMedCrossRefGoogle Scholar
  141. 141.
    Pirskanen R, Tiilikainen A, Hokkanen E. (1972) Histocompatibility (HL-A) antigens associated with myasthenia gravis: a preliminary report. Ann. Clin. Res. 4:304–6.PubMedGoogle Scholar
  142. 142.
    Kaakinen A, Pirskanen R, Tiilikainen A. (1975) LD antigens associated with HL-A8 and myasthenia gravis. Tissue Antigens. 6:175–12.PubMedCrossRefGoogle Scholar
  143. 143.
    Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. (1980) Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 103:579–601.PubMedCrossRefGoogle Scholar
  144. 144.
    Giraud M, et al. (2001) Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology. 57:1555–60.PubMedCrossRefGoogle Scholar
  145. 145.
    Giraud M, Vandiedonck C, Garchon H-J. (2008) Genetic factors in autoimmune myasthenia gravis. Ann. N. Y. Acad. Sci. 1132:180–92.PubMedCrossRefGoogle Scholar
  146. 146.
    Arnett FC, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315–24.PubMedPubMedCentralCrossRefGoogle Scholar
  147. 147.
    Isennock M, Grosel JM. (2011) Juvenile idiopathic arthritis: can you recognize this complex diagnosis? JAAPA. 24:22–7.PubMedGoogle Scholar
  148. 148.
    Harris ED. (1990) Rheumatoid arthritis: pathophysiology and implications for therapy. N. Engl. J. Med. 322:1277–89.PubMedCrossRefGoogle Scholar
  149. 149.
    Modesto C, et al. (2010) Incidence and prevalence of juvenile idiopathic arthritis in Catalonia (Spain). Scand. J. Rheumatol. 39:472–9.PubMedCrossRefGoogle Scholar
  150. 150.
    Andersson Gäre B. (1999) Juvenile arthritis: who gets it, where and when? A review of current data on incidence and prevalence. Clin. Exp. Rheumatol. 17:367–74.PubMedGoogle Scholar
  151. 151.
    Phelan JD, Thompson SD, Glass DN. (2006) Susceptibility to JRA/JIA: complementing general autoimmune and arthritis traits. Genes Immun. 7:1–10.PubMedCrossRefGoogle Scholar
  152. 152.
    Silman AJ, et al. (1993) Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br. J. Rheumatol. 32:903–7.PubMedCrossRefGoogle Scholar
  153. 153.
    Källberg H, et al. (2011) Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann. Rheum. Dis. 70:508–11.PubMedCrossRefGoogle Scholar
  154. 154.
    Roudier J. (2006) HLA-DRB1 genes and extraarticular rheumatoid arthritis. Arthritis Res. Ther. 8:103.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    El-Gabalawy HS, et al. (1999) Association of HLA alleles and clinical features in patients with synovitis of recent onset. Arthritis Rheum. 42:1696–705.PubMedCrossRefGoogle Scholar
  156. 156.
    Glass DN, Litvin DA. (1980) Heterogeneity of HLA associations in systemic onset juvenile rheumatoid arthritis. Arthritis Rheum. 23:796–9.PubMedCrossRefGoogle Scholar
  157. 157.
    Avila-Portillo LM, Vargas-Alarcón G, Andrade F, Alarcón-Segovia D, Granados J. (1994) Linkage disequilibrium of HLA-DR3 and HLA-DR4 with HLA-B alleles in Mexican patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 12:497–502.PubMedGoogle Scholar
  158. 158.
    Hajeer AH, Worthington J, Silman AJ, Ollier WE. (1996) Association of tumor necrosis factor microsatellite polymorphisms with HLA-DRB1*04-bearing haplotypes in rheumatoid arthritis patients. Arthritis Rheum. 39:1109–14.PubMedCrossRefGoogle Scholar
  159. 159.
    Lee H-S, et al. (2008) Several regions in the major histocompatibility complex confer risk for anti-CCP-antibody positive rheumatoid arthritis, independent of the DRB1 locus. Mol. Med. 14:293–300.PubMedPubMedCentralCrossRefGoogle Scholar
  160. 160.
    Miller ML, et al. (1984) Inherited predisposition to iridocyclitis with juvenile rheumatoid arthritis: selectivity among HLA-DR5 haplotypes. Proc. Natl. Acad. Sci. U. S. A. 81:3539–42.PubMedPubMedCentralCrossRefGoogle Scholar
  161. 161.
    Säilä H, et al. (2004) HLA and susceptibility to juvenile idiopathic arthritis: a study of affected sibpairs in an isolated Finnish population. J. Rheumatol. 31:2281–5.PubMedGoogle Scholar
  162. 162.
    Hollenbach JA, et al. (2010) Juvenile idiopathic arthritis and HLA class I and class II interactions and age-at-onset effects. Arthritis Rheum. 62:1781–91.PubMedPubMedCentralCrossRefGoogle Scholar
  163. 163.
    Begovich AB, et al. (2004) A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75:330–7.PubMedPubMedCentralCrossRefGoogle Scholar
  164. 164.
    Suzuki A, et al. (2003) Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 34:395–402.PubMedPubMedCentralCrossRefGoogle Scholar
  165. 165.
    Gregersen PK. (2010) Susceptibility genes for rheumatoid arthritis: a rapidly expanding harvest. Bull. NYU Hosp. Jt. Dis. 68:179–82.PubMedGoogle Scholar
  166. 166.
    Miterski B, et al. (2004) Complex genetic predisposition in adult and juvenile rheumatoid arthritis. BMC Genet. 5:2.PubMedPubMedCentralCrossRefGoogle Scholar
  167. 167.
    Prahalad S. (2004) Genetics of juvenile idiopathic arthritis: an update. Curr. Opin. Rheumatol. 16:588–94.PubMedCrossRefGoogle Scholar
  168. 168.
    Zhernakova A, van Diemen CC, Wijmenga C. (2009) Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat. Rev. Genet. 10:43–55.PubMedCrossRefGoogle Scholar
  169. 169.
    Appenzeller S, Pallone AT, Natalin RA, Costallat LTL. (2009) Prevalence of thyroid dysfunction in systemic lupus erythematosus. J. Clin. Rheumatol. 15:117–9.PubMedCrossRefGoogle Scholar
  170. 170.
    Antonelli A, et al. (2010) Prevalence of thyroid dysfunctions in systemic lupus erythematosus. Metab. Clin. Exp. 59:896–900.PubMedCrossRefGoogle Scholar
  171. 171.
    Candore G, Lio D, Colonna Romano G, Caruso C. (2002) Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. Autoimmun. Rev. 1:29–35.PubMedCrossRefGoogle Scholar
  172. 172.
    Barcellos LF, et al. (2009) High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS. Genet. 5:e1000696.PubMedPubMedCentralCrossRefGoogle Scholar
  173. 173.
    Eike MC, Becker T, Humphreys K, Olsson M, Lie BA. (2009) Conditional analyses on the T1DGC MHC dataset: novel associations with type 1 diabetes around HLA-G and confirmation of HLA-B. Genes Immun. 10:56–67.PubMedCrossRefGoogle Scholar
  174. 174.
    Cheung YH, Watkinson J, Anastassiou D. (2011) Conditional meta-analysis stratifying on detailed HLA genotypes identifies a novel type 1 diabetes locus around TCF19 in the MHC. Hum. Genet. 129:161–76.PubMedCrossRefGoogle Scholar
  175. 175.
    Fernando MMA, et al. (2008) Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS. Genet. 4:e1000024.PubMedPubMedCentralCrossRefGoogle Scholar
  176. 176.
    Cucca F, et al. (1998) Evaluation of IgA deficiency in Sardinians indicates a susceptibility gene is encoded within the HLA class III region. Clin. Exp. Immunol. 111:76–80.PubMedPubMedCentralCrossRefGoogle Scholar
  177. 177.
    Schroeder HW Jr, et al. (1998) Susceptibility locus for IgA deficiency and common variable immunodeficiency in the HLA-DR3, -B8, -A1 haplotypes. Mol. Med. 4:72–86.PubMedPubMedCentralCrossRefGoogle Scholar
  178. 178.
    De la Concha EG, et al. (2002) MHC susceptibility genes to IgA deficiency are located in different regions on different HLA haplotypes. J. Immunol. 169:4637–43.PubMedCrossRefGoogle Scholar
  179. 179.
    Cree BAC, et al. (2010) A major histocompatibility class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01. PLoS ONE. 5:e11296.PubMedPubMedCentralCrossRefGoogle Scholar
  180. 180.
    Vignal C, et al. (2009) Genetic association of the major histocompatibility complex with rheumatoid arthritis implicates two non-DRB1 loci. Arthritis Rheum. 60:53–62.PubMedCrossRefGoogle Scholar
  181. 181.
    Steck AK, Rewers MJ. (2011) Genetics of type 1 diabetes. Clin. Chem. 57:176–85.PubMedPubMedCentralCrossRefGoogle Scholar
  182. 182.
    Buin D, Truedsson L, Hammarström L, Smith CI, Sjöholm AG. (1991) C4 polymorphism and major histocompatibility complex haplotypes in IgA deficiency: association with C4A null haplotypes. Exp. Clin. Immunogenet. 8:233–41.Google Scholar
  183. 183.
    Boodhoo A, et al. (2004) A promoter polymorphism in the central MHC gene, IKBL, influences the binding of transcription factors USF1 and E47 on disease-associated haplotypes. Gene Expr. 12:1–11.PubMedCrossRefGoogle Scholar
  184. 184.
    Price P, et al. (2004) Polymorphisms at positions −22 and −348 in the promoter of the BAT1 gene affect transcription and the binding of nuclear factors. Hum. Mol. Genet. 13:967–74.PubMedCrossRefGoogle Scholar
  185. 185.
    Morzycka-Wroblewska E, Munshi A, Ostermayer M, Harwood JI, Kagnoff MF. (1997) Differential expression of HLA-DQA1 alleles associated with promoter polymorphism. Immunogenetics. 45:163–70.PubMedCrossRefGoogle Scholar
  186. 186.
    Yan Z, et al. (2007) Resequencing of the human major histocompatibility complex in patients with rheumatoid arthritis and healthy controls in Alaska Natives of Southeast Alaska. Tissue Antigens. 70:487–94.PubMedCrossRefGoogle Scholar
  187. 187.
    Asahina Y, et al. (2008) Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. Gastroenterology. 134:1396–405.PubMedCrossRefGoogle Scholar
  188. 188.
    Liu S, et al. (2009) IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. Hum. Mol. Genet. 18:358–65.PubMedCrossRefGoogle Scholar
  189. 189.
    Chistiakov DA. (2010) Interferon induced with helicase C domain 1 (IFIH1) and virus-induced autoimmunity: a review. Viral Immunol. 23:3–15.PubMedCrossRefGoogle Scholar
  190. 190.
    Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. (2009) Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science. 324:387–9.PubMedPubMedCentralCrossRefGoogle Scholar
  191. 191.
    Gateva V, et al. (2009) A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat. Genet. 41:1228–33.PubMedPubMedCentralCrossRefGoogle Scholar
  192. 192.
    Gono T, et al. (2010) Interferon-induced helicase (IFIH1) polymorphism with systemic lupus erythematosus and dermatomyositis/polymyositis. Mod. Rheumatol. 20:466–70.PubMedCrossRefGoogle Scholar
  193. 193.
    Sutherland A, et al. (2007) Genomic polymorphism at the interferon-induced helicase (IFIH1) locus contributes to Graves’ disease susceptibility. J. Clin. Endocrinol. Metab. 92:3338–41.PubMedCrossRefGoogle Scholar
  194. 194.
    Zhao Z-F, et al. (2007) The A946T polymorphism in the interferon induced helicase gene does not confer susceptibility to Graves’ disease in Chinese population. Endocrine. 32:143–7.PubMedCrossRefGoogle Scholar
  195. 195.
    Penna-Martinez M, et al. (2009) The rs1990760 polymorphism within the IFIH1 locus is not associated with Graves’ disease, Hashimoto’s thyroiditis and Addison’s disease. BMC Med. Genet. 10:126.PubMedPubMedCentralCrossRefGoogle Scholar
  196. 196.
    Todd JA, et al. (2007) Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. 39:857–64.PubMedPubMedCentralCrossRefGoogle Scholar
  197. 197.
    International Multiple Sclerosis Genetics Consortium (IMSGC). (2009) The expanding genetic overlap between multiple sclerosis and type I diabetes (2009) Genes Immun. 10:11–4.CrossRefGoogle Scholar
  198. 198.
    Wellcome Trust Case Control Consortium. (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 447:661–78.CrossRefGoogle Scholar
  199. 199.
    Hakonarson H, et al. (2007) A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature. 448:591–4.PubMedCrossRefGoogle Scholar
  200. 200.
    Zoledziewska M, et al. (2009) Variation within the CLEC16A gene shows consistent disease association with both multiple sclerosis and type 1 diabetes in Sardinia. Genes Immun. 10:15–7.PubMedCrossRefGoogle Scholar
  201. 201.
    Wu X, et al. (2009) Intron polymorphism in the KIAA0350 gene is reproducibly associated with susceptibility to type 1 diabetes (T1D) in the Han Chinese population. Clin. Endocrinol. (Oxf). 71:46–9.PubMedCrossRefGoogle Scholar
  202. 202.
    Reddy MPL, et al. (2011) Association between type 1 diabetes and GWAS SNPs in the southeast US Caucasian population. Genes Immun. 12:208–12.PubMedPubMedCentralCrossRefGoogle Scholar
  203. 203.
    Martinez A, et al. (2010) Chromosomal region 16p13: further evidence of increased predisposition to immune diseases. Ann. Rheum. Dis. 69:309–11.PubMedCrossRefGoogle Scholar
  204. 204.
    Dubois PCA, et al. (2010) Multiple common variants for celiac disease influencing immune gene expression. Nat. Genet. 42:295–302.PubMedPubMedCentralCrossRefGoogle Scholar
  205. 205.
    Dema B, et al. (2009) Autoimmune disease association signals in CIITA and KIAA0350 are not involved in celiac disease susceptibility. Tissue Antigens. 73:326–9.PubMedCrossRefGoogle Scholar
  206. 206.
    Awata T, et al. (2009) Association of type 1 diabetes with two loci on 12q13 and 16p13 and the influence coexisting thyroid autoimmunity in Japanese. J. Clin. Endocrinol. Metab. 94:231–5.PubMedCrossRefGoogle Scholar
  207. 207.
    Hodge SE, et al. (2006) Possible interaction between HLA-DRbeta1 and thyroglobulin variants in Graves’ disease. Thyroid. 16:351–5.PubMedCrossRefGoogle Scholar
  208. 208.
    Takahashi M, Kimura A. (2010) HLA and CTLA4 polymorphisms may confer a synergistic risk in the susceptibility to Graves’ disease. J. Hum. Genet. 55:323–6.PubMedCrossRefGoogle Scholar
  209. 209.
    Kula D, et al. (2006) Interaction of HLA-DRB1 alleles with CTLA-4 in the predisposition to Graves’ disease: the impact of DRB1*07. Thyroid. 16:447–53.PubMedCrossRefGoogle Scholar
  210. 210.
    Aminkeng F, et al. (2009) IFIH1 gene polymorphisms in type 1 diabetes: genetic association analysis and genotype-phenotype correlation in the Belgian population. Hum. Immunol. 70:706–10.PubMedCrossRefGoogle Scholar
  211. 211.
    Smyth DJ, et al. (2008) PTPN22 Trp620 explains the association of chromosome 1p13 with type 1 diabetes and shows a statistical interaction with HLA class II genotypes. Diabetes. 57:1730–7.PubMedCrossRefGoogle Scholar
  212. 212.
    Steck AK, et al. (2006) Association of the PTPN22/LYP gene with type 1 diabetes. Pediatr. Diabetes. 7:274–8.PubMedCrossRefGoogle Scholar
  213. 213.
    Hermann R, et al. (2006) Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes. Diabetologia. 49:1198–208.PubMedCrossRefGoogle Scholar
  214. 214.
    Bjørnvold M, et al. (2006) FOXP3 polymorphisms in type 1 diabetes and coeliac disease. J. Autoimmun. 27:140–4.PubMedCrossRefGoogle Scholar
  215. 215.
    Taylor KE, et al. (2011) Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS. Genet. 7:e1001311.PubMedPubMedCentralCrossRefGoogle Scholar
  216. 216.
    Hoddinott S, Dornan J, Bear JC, Farid NR. (1982) Immunoglobulin levels, immunodeficiency and HLA in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 23:326–9.PubMedCrossRefGoogle Scholar
  217. 217.
    Bertrams J, Schoeps L, Baur MP, Luboldt W, van Loghem E. (1983) IgG and IgA heavy chain allotypes in type 1 diabetes. J. Immunogenet. 10:305–10.PubMedCrossRefGoogle Scholar
  218. 218.
    Page SR, Lloyd CA, Hill PG, Peacock I, Holmes GK. (1994) The prevalence of coeliac disease in adult diabetes mellitus. QJM 87:631–7.PubMedGoogle Scholar
  219. 219.
    Acerini CL, et al. (1998) Coeliac disease in children and adolescents with IDDM: clinical characteristics and response to gluten-free diet. Diabet. Med. 15:38–44.PubMedCrossRefGoogle Scholar
  220. 220.
    Schober E, et al. (2000) Screening by antiendomysium antibody for celiac disease in diabetic children and adolescents in Austria. J. Pediatr. Gastroenterol. Nutr. 30:391–6.PubMedCrossRefGoogle Scholar
  221. 221.
    Laadhar L, et al. (2006) Prevalence of celiac disease serological markers in Tunisian type 1 diabetic adults [in French]. Ann. Biol. Clin. (Paris). 64:439–44.PubMedGoogle Scholar
  222. 222.
    Sayarifard F, et al. (2010) Evaluation of serum IgA levels in Iranian patients with type 1 diabetes mellitus. Acta Diabetol. 2010, Apr 22. [Epub ahead of print].Google Scholar
  223. 223.
    Sardi J, Casellas F, de Torres I, Malagelada JR. (2000) Clinical relevance of immunoglobulin A deficiency in celiac disease [in Spanish]. Med. Clin. (Barc). 115:687–9.PubMedCrossRefGoogle Scholar
  224. 224.
    Bundey S, Doniach D, Soothill JF. (1972) Immunological studies in patients with juvenileonset myasthenia gravis and in their relatives. Clin. Exp. Immunol. 11:321–32.PubMedPubMedCentralGoogle Scholar
  225. 225.
    Lisak RP, Zweiman B. (1976) Serum immunogloblin levels in myasthenia gravis, polymyositis, and dermatomyositis. J. Neurol. Neurosurg. Psychiatr. 39:34–7.CrossRefGoogle Scholar
  226. 226.
    Bramis J, Sloane C, Papatestas A, Genkins G, Aufses A. (1976) Serum-IgA in myasthenia gravis. Lancet. 307:1243–4.CrossRefGoogle Scholar
  227. 227.
    Behan P, Simpson J, Behan WH. (1976) Decreased serum-IgA in myasthenia gravis. Lancet. 307:593–4.CrossRefGoogle Scholar
  228. 228.
    Liblau R, Fischer AM, Shapiro DE, Morel E, Bach JF. (1992) The frequency of selective IgA deficiency in myasthenia gravis. Neurology. 42:516–8.PubMedCrossRefGoogle Scholar
  229. 229.
    Bluestone R, Goldberg LS, Katz RM, Marchesano JM, Calabro JJ. (1970) Juvenile rheumatoid arthritis: a serologic survey of 200 consecutive patients. J. Pediatr. 77:98–102.PubMedCrossRefGoogle Scholar
  230. 230.
    Panush RS, et al. (1972) Juvenile rheumatoid arthritis: cellular hypersensitivity and selective IgA deficiency. Clin. Exp. Immunol. 10:103–15.PubMedPubMedCentralGoogle Scholar
  231. 231.
    Salmi TT, Schmidt E, Laaksonen AL, Anttila R, Kouvalainen K. (1973) Levels of serum immunoglobulins in juvenile rheumatoid arthritis. Ann. Clin. Res. 5:395–7.PubMedGoogle Scholar
  232. 232.
    Cassidy JT, Petty RE, Sullivan DB. (1973) Abnormalities in the distribution of serum immunoglobulin concentrations in juvenile rheumatoid arthritis. J. Clin. Invest. 52:1931–6.PubMedPubMedCentralCrossRefGoogle Scholar
  233. 233.
    Cassidy JT, Petty RE, Sullivan DB. (1977) Occurrence of selective iga deficiency in children with juvenile rheumatoid arthritis. Arthritis and Rheumatism. 20:181–3.Google Scholar
  234. 234.
    Barkley DO, Hohermuth HJ, Howard A, Webster DB, Ansell BM. (1979) IgA deficiency in juvenile chronic polyarthritis. J. Rheumatol. 6:219–24.PubMedGoogle Scholar
  235. 235.
    Pelkonen P, Savilahti E, Mäkelä AL. (1983) Persistent and transient IgA deficiency in juvenile rheumatoid arthritis. Scand. J. Rheumatol. 12:273–9.PubMedCrossRefGoogle Scholar
  236. 236.
    Moradinejad MH, et al. (2011) Prevalence of IgA deficiency in children with juvenile rheumatoid arthritis. Iran J. Allergy Asthma Immunol. 10:35–40.PubMedGoogle Scholar
  237. 237.
    Natvig JB, Harboe M, Fausa O, Tveit A. (1971) Family studies in individuals with selective absence of gamma-A-globulin. Clin. Exp. Immunol. 8:229–36.PubMedPubMedCentralGoogle Scholar
  238. 238.
    Thakar YS, Chande C, Dhanvijay AG, Pande S, Saoji AM. (1997) Analysis of immunoglobulin deficiency cases: a five year study. Indian J. Pathol. Microbiol. 40:309–13.PubMedGoogle Scholar
  239. 239.
    Badcock LJ, Clarke S, Jones PW, Dawes PT, Mattey DL. (2003) Abnormal IgA levels in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62:83–4.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2011

Authors and Affiliations

  • Ning Wang
    • 1
  • Nan Shen
    • 2
  • Timothy J. Vyse
    • 3
  • Vidya Anand
    • 3
  • Iva Gunnarson
    • 4
  • Gunnar Sturfelt
    • 5
  • Solbritt Rantapää-Dahlqvist
    • 6
  • Kerstin Elvin
    • 7
  • Lennart Truedsson
    • 8
  • Bengt A. Andersson
    • 9
  • Charlotte Dahle
    • 10
  • Eva Örtqvist
    • 11
  • Peter K. Gregersen
    • 12
  • Timothy W. Behrens
    • 13
  • Lennart Hammarström
    • 1
  1. 1.Division of Clinical Immunology, Department of Laboratory MedicineKarolinska Institutet at Karolinska University Hospital HuddingeStockholmSweden
  2. 2.Department of Rheumatology, Renji HospitalJiaoTong University School of MedicineShanghaiChina
  3. 3.Section of Molecular Genetics and RheumatologyHammersmith HospitalLondonUK
  4. 4.Rheumatology Unit, Department of MedicineKarolinska University Hospital SolnaStockholmSweden
  5. 5.Department of RheumatologyLund University HospitalLundSweden
  6. 6.Department of RheumatologyUniversity HospitalUmeåSweden
  7. 7.Unit of Clinical Immunology, Department of Clinical Immunology and Transfusion MedicineKarolinska University Hospital HuddingeStockholmSweden
  8. 8.Department of Laboratory Medicine, Section of Microbiology, Immunology and GlycobiologyLund UniversityLundSweden
  9. 9.Department of ImmunologySahlgrenska AcademyGothenburgSweden
  10. 10.Clinical Immunology Unit, Department of Clinical and Experimental MedicineLinköping UniversityLinköpingSweden
  11. 11.Department of Woman and Child Health, Astrid Lindgren Children’s HospitalKarolinska University Hospital SolnaStockholmSweden
  12. 12.Robert S. Boas Center for Genomics and Human GeneticsFeinstein Institute for Medical ResearchManhassetUSA
  13. 13.Division of Immunology, Tissue Growth & Repair, Biomarker Discovery and Human GeneticsGenentechSouth San FranciscoUSA

Personalised recommendations